Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

ABSTRACT: The purpose of this phase III study is to evaluate the safety and efficacy of the combination of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis (FAP).

DISEASE(S): Adenomatous Polyposis Coli,Colorectal Neoplasms,Familial Adenomatous Polyposis,Nasopharyngeal Neoplasms

PROVIDER: 2098444 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Project description:The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. This includes: 1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or 2) clinically important events which includes progression to more advanced duodenal polyposis, cancer or death.

| 2116545 | ecrin-mdr-crc

Expression data of Familial adenomatous polyposis (FAP) organoids

Project description:Expression data of Familial adenomatous polyposis (FAP) organoids

| PRJNA432078 | ENA

SNP data of Familial adenomatous polyposis (FAP) organoids

Project description:SNP data of Familial adenomatous polyposis (FAP) organoids

| PRJNA432077 | ENA

Mucosa samples from patients with Familial Adenomatous Polyposis (FAP)

Project description:Mucosa samples from patients with Familial Adenomatous Polyposis (FAP)

| PRJNA561096 | ENA

Expression data and SNP data of Familial adenomatous polyposis (FAP) organoids

Project description:Expression data and SNP data of Familial adenomatous polyposis (FAP) organoids

| PRJNA432073 | ENA

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

Project description:This randomized phase II trial studies how well giving celecoxib with or without eflornithine works in preventing colorectal cancer in patients with familial adenomatous polyposis. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib and eflornithine may keep cancer from forming in patients with familial adenomatous polyposis.

| 2007350 | ecrin-mdr-crc

SNP data of Familial adenomatous polyposis (FAP) organoids

Project description:FAP is an autosomal-dominant inherited disease caused by germline mutations in the APC gene 1. Two major FAP phenotypes, CFAP and AFAP, can be distinguished based on polyp numbers and age of onset. CFAP is characterized by the presence of hundreds to thousands of polyps. About half of these patients develop adenomas by age 15, and 95% develop adenomas by age 35. AFAP patients exhibit a milder phenotype than CFAP patients; AFAP is characterized by fewer polyps, later adenoma onset, and lower CRC risk. We used microarrays to analyze chromosome abberation of organids established from FAP patients.

2019-12-31 | GSE109813 | GEO

Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis

Project description:Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis

| PRJNA656959 | ENA

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

Project description:To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).

| 2048402 | ecrin-mdr-crc

Mucosa samples from patients with Familial Adenomatous Polyposis (FAP)

Project description:The genetic alterations of intestinal carcinogensis have been observed in multiple comparative studies. However, transcriptomic characteristics of at-risk muocsa and adenomas from patients with FAP are still lacking. Therefore, our aim was to characterize the transcriptomic profile of at-risk mucosa of FAP patients.

2021-08-19 | GSE136044 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data